Uniformed Services University of the Health Sciences, USA.
Endocrinology Department, David Grant USAF Medical Center, Travis AFB, CA 94535, USA.
Mil Med. 2024 Jan 23;189(1-2):e439-e442. doi: 10.1093/milmed/usad283.
Clinicians may confuse an impaired sensitivity to thyroid hormone with hyperthyroidism and offer an inappropriate treatment. We report a diagnosis of resistance to thyroid hormone (RTH) caused by a rare mutation in the thyroid hormone receptor beta gene in a patient previously presumed to have Graves' disease. We have found only one published case of a novel point mutation, c.749T>C (p.Ile250Thr variant) associated with 50% reduction in thyroid hormone receptor binding affinity for triiodothyronine in the I250T mutant; it was found in this patient. A 66-year-old male veteran, with a history of non-ischemic cardiomyopathy and arrhythmias, was referred by a cardiologist with concerns for a possible thyrotropin (TSH) adenoma on account of elevated TSH and free thyroxine (FT4) levels. Pituitary imaging was negative. He was previously treated with radioiodine for presumptive Graves' disease in the civilian sector. Examination revealed a goiter with no nodules. Repeat TSH and FT4 levels were elevated and also free triiodothyronine (FT3) and reverse triiodothyronine. These findings and other test results were consistent with RTH, which was confirmed by genetic testing. Mutation analysis showed the patient to be heterozygous for the p.Ile250Thr variant. He later developed hypothyroidism. Resistance to thyroid hormone can be misdiagnosed as hyperthyroidism with consequent inappropriate treatment. Treatment is not needed in most RTH-beta patients. Thyroid ablation should generally be avoided. Clinicians must be cautious whenever they encounter concurrent elevation of TSH, FT4, and FT3. This RTH-beta patient has a rare I250T mutant of the thyroid hormone receptor beta gene, the second reported case in the literature.
临床医生可能会将甲状腺激素敏感性受损与甲状腺功能亢进混淆,并提供不适当的治疗。我们报告了一例由甲状腺激素受体β基因罕见突变引起的抵抗甲状腺激素(RTH)的诊断,该患者先前被认为患有格雷夫斯病。我们仅发现了一例与甲状腺激素受体结合亲和力降低 50%相关的 novel point mutation,c.749T>C(p.Ile250Thr 变体)的文献报道,该突变存在于该患者中。一位 66 岁的男性退伍军人,有非缺血性心肌病和心律失常病史,因 TSH 和游离甲状腺素(FT4)水平升高,被心脏病专家转介,怀疑可能存在促甲状腺激素(TSH)腺瘤。垂体成像为阴性。他之前曾在平民区因疑似格雷夫斯病接受过放射性碘治疗。检查发现甲状腺肿大,无结节。重复 TSH 和 FT4 水平升高,游离三碘甲状腺原氨酸(FT3)和反三碘甲状腺原氨酸也升高。这些发现和其他测试结果与 RTH 一致,基因检测证实了这一点。突变分析显示该患者为 p.Ile250Thr 变体杂合子。他后来出现了甲状腺功能减退。抵抗甲状腺激素可误诊为甲状腺功能亢进,导致治疗不当。大多数 RTH-β 患者不需要治疗。甲状腺消融一般应避免。临床医生在遇到 TSH、FT4 和 FT3 同时升高时必须谨慎。这位 RTH-β 患者的甲状腺激素受体β基因存在罕见的 I250T 突变,这是文献中第二例报道。